• Ibuprofen: A Cyclooxygenase Inhibitor for Cancer and Athe...

  2026-04-06

  Ibuprofen’s dual COX-1/COX-2 inhibition and apoptosis-inducing capabilities make it indispensable for advanced studies in colon cancer and lipid metabolism. This guide details optimized workflows, troubleshooting strategies, and experimental innovations powered by APExBIO’s high-purity Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid). Discover how to maximize reproducibility and mechanistic insights across inflammation, cancer biology, and atherosclerosis models.

• Cisplatin in Cancer Research: Linking DNA Damage to RNA m...

  2026-04-06

  Explore the multifaceted role of cisplatin, a gold-standard chemotherapeutic compound, as both a DNA crosslinking agent and a tool to probe RNA m6A homeostasis and genome stability in cancer research. Discover advanced mechanistic insights, emerging applications, and translational strategies beyond conventional apoptosis assays.

• Angiotensin III (human, mouse): Core RAAS Peptide for Car...

  2026-04-05

  Angiotensin III (human, mouse) is a validated renin-angiotensin-aldosterone system (RAAS) peptide that robustly induces aldosterone secretion and mediates pressor activity. As a precise AT1 and AT2 receptor ligand, it supports reproducible cardiovascular and neuroendocrine research protocols.

• Cisplatin as a Mechanistic Probe: DNA Damage, Apoptosis, ...

  2026-04-04

  Explore how Cisplatin, a gold-standard DNA crosslinking agent, enables precise mechanistic studies in cancer research. This article uniquely examines its roles in apoptosis, oxidative stress, and chemoresistance, providing a deeper analysis than typical application guides.

• Diclofenac: Non-Selective COX Inhibitor for Inflammation ...

  2026-04-03

  Diclofenac is a highly pure, non-selective cyclooxygenase (COX) inhibitor widely used for inflammation and pain signaling research. Its robust solubility in DMSO and ethanol, combined with reliable inhibition of prostaglandin synthesis, make it a gold standard compound for COX enzyme assays and advanced organoid pharmacokinetic models. This dossier clarifies Diclofenac’s properties, best practices, and critical boundaries for research use.

• (S)-(+)-Ibuprofen: Mechanistic Insights and Emerging Fron...

  2026-04-03

  (S)-(+)-Ibuprofen, the pharmacologically active ibuprofen enantiomer, is a cornerstone COX inhibitor for advanced inflammation and pain mechanism studies. This article delivers a distinctive, in-depth analysis of its mechanistic action, synthetic progress, and next-generation applications—bridging molecular insights with translational research opportunities.

• Cisplatin in Cancer Research: Mechanisms, Chemoresistance...

  2026-04-02

  Explore the multifaceted role of Cisplatin as a DNA crosslinking agent for cancer research, with a special focus on apoptosis, chemoresistance, and patient-derived xenograft models. Uncover advanced scientific insights and practical guidance on leveraging Cisplatin’s mechanisms for translational oncology.

• (S)-(+)-Ibuprofen: Selective COX Inhibitor for Inflammati...

  2026-04-02

  (S)-(+)-Ibuprofen is a pharmacologically active ibuprofen enantiomer and a benchmark COX inhibitor widely used in inflammation pathway and pain mechanism studies. Its selective inhibition of COX-1 and COX-2, along with high solubility in DMSO and ethanol, make it ideal for in vitro and in vivo research. Compared to its R-enantiomer, (S)-(+)-Ibuprofen exhibits stronger activity and fewer side effects.

• Angiotensin III (human, mouse): Advanced Mechanistic Insi...

  2026-04-01

  Discover the multifaceted role of Angiotensin III, a key renin-angiotensin-aldosterone system peptide, as both an aldosterone secretion inducer and a pressor activity mediator. This article provides in-depth analysis of its unique receptor interactions, translational applications, and emerging implications for cardiovascular, neuroendocrine, and viral pathogenesis research.

• (S)-(+)-Ibuprofen: Chemical Structure, COX Inhibition, an...

  2026-04-01

  (S)-(+)-Ibuprofen is the pharmacologically active ibuprofen enantiomer, renowned for selective COX inhibition and translational research value. This article uniquely explores its chemical makeup, cutting-edge assay applications, and future directions for inflammation and pain management science.

• Cisplatin in Cancer Research: From Molecular Mechanisms t...

  2026-03-31

  Explore the multifaceted role of Cisplatin as a DNA crosslinking agent for cancer research, with a special focus on apoptosis, chemoresistance, and the interplay with immune checkpoint regulation. Discover how cutting-edge insights into ER stress and PD-L1 stabilization open new avenues for therapeutic innovation.

• Diclofenac: Advanced Approaches for Inflammation and Phar...

  2026-03-31

  Explore how Diclofenac, a non-selective COX inhibitor, is redefining inflammation and pain signaling pathway research with new in vitro and pharmacokinetic models. This article delivers deep scientific insights and practical guidance for leveraging Diclofenac in innovative research applications.

• Ibuprofen (A8446): Cyclooxygenase Inhibitor for Cancer & ...

  2026-03-30

  Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) and dual cyclooxygenase inhibitor, is a benchmark agent for anti-proliferative and anti-inflammatory studies. APExBIO’s Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) demonstrates reproducible activity in cancer, atherosclerosis, and pain models, with well-defined mechanisms and solubility parameters.

• Cisplatin in Translational Oncology: Mechanistic Rigor, S...

  2026-03-30

  This thought-leadership article provides a comprehensive, mechanistic, and strategic roadmap for translational researchers employing Cisplatin—a gold-standard DNA crosslinking agent—in cancer research. Integrating molecular insights, translational challenges, and actionable guidance, the article explores how APExBIO’s Cisplatin (SKU A8321) empowers rigorous apoptosis assays, chemoresistance studies, and next-generation xenograft models. Drawing on recent evidence—including the pivotal role of Smurf1 in modulating chemosensitivity—the discussion advances beyond conventional product pages to inspire innovation and reproducibility in preclinical and translational oncology.

• Ibuprofen as an Anti-Proliferative Agent in Colon Cancer ...

  2026-03-29

  APExBIO’s Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) empowers researchers with a robust, reproducible cyclooxygenase inhibitor for advanced cancer, inflammation, and atherosclerosis models. This guide delivers hands-on protocols, troubleshooting insights, and comparative analysis to maximize Ibuprofen’s impact as an anti-proliferative agent in translational research.

16291 records 1/1087 page Next 12345 下5页 Last page